In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 18 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

3D myocardial strain analysis using 320-slice computed tomographic data is useful for the detection of myocardial fibrosis in hypertrophic cardiomyopathy

Session Clinical impact of strain imaging

Speaker Assistant Professor Hiroyuki Takaoka

Event : ESC Congress 2018

  • Topic : imaging
  • Sub-topic : Computed Tomography: Technology
  • Session type : Abstract Session

Authors : H Takaoka (Chiba,JP), N Funabashi (Chiba,JP), K Ozawa (Chiba,JP), Y Kobayashi (Chiba,JP)

Authors:
H. Takaoka1 , N. Funabashi1 , K. Ozawa1 , Y. Kobayashi1 , 1Chiba University Graduate School of Medicine - Chiba - Japan ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 1042

Background: Myocardial strain is useful for early detection of left ventricular myocardial (LVM) damage but is usually determined by 2 dimensional (2D) speckle tracking TTE. A novel prototype software program (Physiodynamics, Ziosoft) can calculate 3D strain values in LVM using existing 320 slice CT, which is in daily clinical use.

Purpose: To evaluate the usefulness of myocardial strain analysis on CT for detection of myocardial fibrosis in cases with hypertrophic cardiomyopathy (HCM).

Methods: Eighteen consecutive HCM patients who underwent 320 slice CT (Aquilion One), 2D speckle tracking transthoracic echocardiography (TTE) (Vivid E9, GE Healthcare), and 1.5T or 3T cardiac magnetic resonance (CMR) (Ingenia or Achieva) were analyzed. Cardiac CT was performed with retrospective ECG gaging with tube current dose modulation. After acquisition, CT images were reconstructed at every 5% of the R-R interval from 0–95% (total, 20 phases). We compared the detectability of a new 3D CT myocardial strain values with that of regional peak longitudinal and circumferential strain (PLS and PCS) on TTE to detect late gadolinium enhancement (LGE) in the LVM on CMR. On CT, the 3D strain ratio (3DSR; segmental 3D strain-value per maximum segmental 3D strain-value in each patient) of each LVM segment was calculated. On TTE, PLS and PCS (both absolute values) for each LVM segment among 17 American Heart Association-defined lesions were calculated.

Results: Using receiver operating characteristic (ROC) analysis for the detection of LGE on CMR, the best cut off value of 3DSR was 0.3 with area under the curve (AUC) of 0.88 (P<0.0001), a sensitivity of 84% and a specificity of 84%. While that of PLS was 12 with an AUC of 0.68 (P<0.0001), a sensitivity of 78% and a specificity of 53%, and that of PCS was 15 with an AUC of 0.51 (P=0.913), a sensitivity of 49% and a specificity of 58%. The AUC was significantly greater in CT than in PLS and in PCS of TTE (both P<0.01).

Conclusion: 3DSR determined by existing CT has a significantly superior detectability for LGE in LVM on CMR than PLS and PCS in HCM patients.

ROC curves

This content is currently on FREE ACCESS, enjoy another 18 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are